<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650830</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0503</org_study_id>
    <nct_id>NCT02650830</nct_id>
  </id_info>
  <brief_title>Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;The goal of this work is to critically test the hypothesis that there exists a different
      profile of bile acids (BAs) in patient with type 2 diabetes mellitus (T2DM) compared with
      normal controls. Through confirmation of different profile of BAs in T2DM, investigator will
      suggest modulation of specific bile acids as a new possible treatment target in patients with
      T2DM. Investigator also expect the specific BAs signature will be used to screen T2DM before
      hyperglycemia.

      In addition, investigator will evaluate the association between each BA species and serum
      total glucagon like peptide-1 (GLP-1) or fibroblast growth factor-19 (FGF-19) concentrations
      to determine if the specific BAs profile is related with total GLP-1 or FGF-19 concentration
      in serum. Investigatr also evaluates the correlation between each BA species and metabolic
      profiles and oxidative stress marker to find possible roles of each BA component in glucose
      metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>bile acid profile</measure>
    <time_frame>8h fasting blood sample</time_frame>
    <description>Bile acids profile to predict T2DM will be measured using high performance liquid chromatography-tandem mass spectrometry.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Prediabetes</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1) Normal control</arm_group_label>
    <description>metabolically healthy with no obesity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2) prediabetes</arm_group_label>
    <description>defined in 'inclusion criteria'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3) type 2 diabetes</arm_group_label>
    <description>defined in 'inclusion criteria'</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum (blood), whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects are recruited from either patients who visit out-patient clinics (Diabetes center
        in Severance hospital) or healthy volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. pre-diabetes 1. defined according to the ADA guideline (prediabetes definition) FPG
             100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG) or 2-h PG in the 75-g OGTT 140
             mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (IGT) or A1C 5.7-6.4% (39-46 mmol/mol)

          2. type 2 diabetes 1. defined according to the ADA guideline (DM definition) FPG ≥126
             mg/dL (7.0 mmol/L) or 2-h PG ≥200 mg/dL (11.1 mmol/L) in the 75-g OGTT or A1C ≥6.5%
             (48 mmol/mol) or In a patient with classic symptoms of hyperglycemia or hyperglycemic
             crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L) or 2. taking any
             anti-diabetic medications

          3. Normal control 1. should not be included in other groups as above and 2. not taking
             any medication related to diabetes and dyslipidemia and 3. BMI &lt;25kg/m2

        Exclusion Criteria:

          1. subjects who refused to agree with informed consents

          2. subjects with organ-transplantation

          3. pregnant women

          4. type 1 diabetes -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeong-Ho Kim, MD</last_name>
    <phone>+82-2-2228-2448</phone>
    <email>jeongho@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong-Ho Kim, MD</last_name>
      <phone>+82 02-2228-2455</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2016</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>prediabetes</keyword>
  <keyword>bile acids profile</keyword>
  <keyword>GLP-1</keyword>
  <keyword>FGF-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Acids and Salts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no plan to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

